Original Article

Effects of Metformin on Endometrial Cancer Cell
Growth in Vivo: A Preoperative Prospective Trial
Akira Mitsuhashi, MD, PhD1; Takako Kiyokawa, MD, PhD2; Yasunori Sato, PhD3; and Makio Shozu, MD, PhD1

BACKGROUND: Metformin, an antidiabetic drug, decreases the incidence of various cancers in diabetic patients. Metformininduced inhibition of cancer cell proliferation has been confirmed in vitro but not in humans. Because endometrial cancer is
associated with insulin resistance, the authors investigated whether a diabetes-therapeutic metformin dose inhibits cancer cell
growth in patients with endometrial cancer. METHODS: A dose of metaformin was administered (1500-2250 mg/day) to 31 patients
with endometrial cancer preoperatively for 4 to 6 weeks. Cell proliferation was assessed in patient tissues using immunohistochemical
and Western blot analyses and DNA synthesis was measured in serum using a thymidine uptake assay. All statistical tests were 2sided. P values of < .05 were considered statistically significant. RESULTS: Preoperative metformin treatment decreased DNA synthesis in sera and significantly reduced the Ki-67 (mean proportional decrease, 44.2%; 95% confidence interval [95% CI], 35.4-53.0
[P <.001]) and topoisomerase IIa (mean proportional decrease, 36.4%; 95% CI, 26.7-46.0 [P <.001]) labeling indices. Levels of
phospho-ribosomal protein S6 and phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) were found to be significantly
decreased and phospho-adenosine monophosphate-activated protein kinase and p27 levels were significantly increased. Preoperative
metformin use caused significant decreases in circulating factors, including insulin, glucose, insulin-like growth factor 1, and leptin.
DNA synthesis-stimulating activity in patient sera was significantly decreased during metformin administration. CONCLUSIONS: An
antidiabetic dose of metformin inhibited endometrial cancer cell growth in vivo, an effect likely due to its effect on humoral factor(s).
C 2014 American
This translational study provides considerable rationale to initiate large clinical trials. Cancer 2014;120:2986-95. V
Cancer Society.
KEYWORDS: metformin, endometrial cancer, insulin resistance, growth inhibition, in vivo.

INTRODUCTION
Metformin, an oral biguanide antihyperglycemic drug, is widely prescribed as first-line therapy against type 2 diabetes
mellitus. Metformin suppresses hepatic gluconeogenesis and increases glucose uptake by peripheral tissues, thereby
decreasing plasma glucose levels and eventually decreasing plasma insulin levels.1
Widespread metformin use over the past decade has inspired several population studies that have identified additional benefits of metformin, including a metformin-induced decrease in cancer incidence and cancer-related mortality in
patients with diabetes.2,3 This applies to cancers of the breast, colon, lung, prostate, pancreas, ovary, and liver. In addition
to cancer prevention, more recent studies have indicated that metformin also possesses antineoplastic properties,4-9 such
as improving response rates to neoadjuvant chemotherapy in patients with breast cancer.10 These epidemiologic findings
suggest that metformin is a promising drug for both cancer prevention and treatment and have facilitated numerous preclinical studies regarding its mechanism of action and therapeutic effects. However, quite a few questions remain to be
answered before clinical trials may be initiated.11 One such question is which type of cancer should be included in introductory clinical studies to establish the benefit of metformin use. Several in vitro studies have demonstrated that metformin causes growth inhibition in various types of cancer cell lines. However, the metformin concentration used for these
studies was much higher than the established in vivo concentration of orally administered metformin; thus, these in vitro
data do not validate all types of cancer cells as clinical targets. Therefore, additional studies are required to establish relevant study models for the investigation of metformin and its anticancer activity.

Corresponding author: Akira Mitsuhashi, MD, PhD, Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana Chuoku, Chiba 260-8670, Japan; Fax: (011) 81-43-226-2122; antira@faculty.chiba-u.jp
1
Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan; 2Department of Molecular Pathology, Graduate School of
Medicine, Chiba University, Chiba, Japan; 3Clinical Research Center, Chiba University Hospital, Chiba, Japan

We thank Dr. Tomomi Hamada of the Iwaki Kusakidai General Clinic for cross-reviewing the pathological diagnoses.
DOI: 10.1002/cncr.28853, Received: January 12, 2014; Revised: March 19, 2014; Accepted: April 28, 2014, Published online June 10, 2014 in Wiley Online
Library (wileyonlinelibrary.com)

2986

Cancer

October 1, 2014

Metformin Effects on Endometrial Cancer/Mitsuhashi et al

In the current study, we investigated the action of
metformin in patients with endometrial cancer because
endometrial cancer is often associated with obesity, insulin resistance, and diabetes,12,13 and a recent retrospective
cohort study on metformin use revealed the highest risk
reduction was in patients with ovarian/endometrial cancer.14 We validated the use of endometrial cancer as a
study model with a short-duration preclinical study using
surrogate markers of therapeutic effects. To the best of
our knowledge, the current study is the first report of a
prospective study demonstrating the clinical benefit of a
diabetes-therapeutic dose of metformin on endometrial
cancer cell proliferation and downstream targets of the
adenosine monophosphate-activated protein kinase
(AMPK)/mammalian target of rapamycin (mTOR) and
mitogen-activated protein kinase (MAPK) pathways.
MATERIALS AND METHODS
Patients

Between January 2011 and May 2013, we recruited 40
consecutive patients with endometrioid adenocarcinoma
who were scheduled to undergo surgery at Chiba University Hospital (Chiba, Japan). Eligibility criteria included
an Eastern Cooperative Oncology Group performance
status of 0 to 1 and normal renal, liver, and cardiac function. Exclusion criteria were as follows: 1) type 2 diabetes
requiring medication; 2) history of metformin use; 3) an
abnormal blood coagulation profile and/or a history of
thromboembolism; and 4) the presence of mental or lifethreatening illnesses. Five patients declined study participation, and 35 patients agreed to participate in the study,
4 of whom experienced intolerable nausea at a metformin
dose of 750 mg and withdrew consent; this resulted in a
final total of 31 patients.
Study Design

The primary objective of the current study was to evaluate
the effects of a diabetes-therapeutic dose of metformin on
cell proliferation activity and growth-related signaling
pathways in endometrial cancer tissues. The secondary
objectives were to evaluate the metabolic effect of metformin on endocrine factors and to investigate the effects of
metformin on the growth-supporting potential of sera.
Metformin (initial dose, 750 mg/day; increased
weekly by 750 mg up to 1500 or 2250 mg/day) was
administered for approximately 4 weeks until the day of
scheduled surgery. Tissue specimens were obtained via endometrial curettage at the time of initial diagnosis (before
treatment) and hysterectomy (after treatment). Changes
in cell proliferation were determined by immunohistoCancer

October 1, 2014

chemistry and Western blot analysis of paired endometrial
tissue specimens. Metformin concentrations were measured in surplus frozen tissue and plasma samples using liquid chromatography-tandem mass spectrometry. Changes
in the growth-stimulating potential of serum were assessed
in paired sera obtained from 15 patients; thymidine incorporation rates in Ishikawa cells, an endometrial cancerderived cell line, were measured in the presence of 2% immobilized patient serum. The metabolic effect of metformin treatment was assessed using a 75-g oral glucose
tolerance test before and during treatment (usually a few
days before surgery and approximately at week 4 of metformin treatment). Pathological diagnoses of endometrial
samples were reviewed by 2 independent pathologists.
The Institutional Review Board of Chiba University
approved the study protocol, and all patients provided
written informed consent before participation. This trial
was registered at umin.ac.jp/ctr/index.htm (identifier
number UMIN 000004852).
Cell Culture

Two endometrial cancer cell lines, HEC-1B and Ishikawa,
were cultured in Dulbecco modified Eagle medium
(DMEM; Life Technologies Corporation, Carlsbad,
Calif) containing 4500 mg/mL of glucose and 10% fetal
bovine serum (FBS; Sigma-Aldrich, St. Louis, Mo), 100
U/mL of penicillin, 100 U/mL of streptomycin, and
2 mM glutamine at 37 C and 5% carbon dioxide. The
HEC-1B cell line was purchased from the JCRB Cell
Bank (Osaka, Japan). The Ishikawa cell line was generously provided by Dr. Nishida (Tsukuba University,
Japan).
Cell Proliferation Assay

Cells were seeded in 12-well plates (25,000 cells/well) in
DMEM containing 10% FBS for 24 hours. The cells were
then treated with increasing doses (0 mM-10 mM) of
metformin for 72 hours. The media were replaced every
24 hours. After the addition of AlamarBlue reagent (Invitrogen, Carlsbad, Calif), the plates were incubated at
37 C, and colorimetric changes were measured.
(3H)Thymidine Incorporation Assay

Ishikawa cells (5 3 103 cells/well in 96-well plates) were
cultured in DMEM containing 10% FBS for 48 hours
until the exponential growth phase was reached, after
which they were cultured with increasing doses (0 mM10 mM) of metformin for 24 hours. Next, the cells were
labeled with (3H)thymidine (1 lCi [37 kBq]/well) (PerkinElmer, Waltham, Mass) for 2.5 hours and harvested
2987

Original Article

onto glass fiber filters using the Tomtec Harvester 96
Mach 3 (Wallac Ltd, Turku, Finland). After extensive
washing with phosphate-buffered saline, radioactivity was
detected on the filter using a Wallac 1450 MicroBeta liquid scintillation counter (Wallac Ltd). Thymidine incorporation was expressed as a percentage of that in untreated
(no metformin) controls. Paired samples (premetaformin
and postmetformin sera from the same patient) were
assayed on the same plate in 5 replicates. A geometrical
mean was used for statistical analysis.
Ex Vivo Assay to Assess the Growth-Stimulatory
Activity of Serum

Ishikawa cells (96-well plates; 5 3 103 cells/well) were
cultured in DMEM containing 10% FBS for 12 hours
and cultured for 72 hours in assay media in which 2% immobilized patient serum replaced 10% FBS. At the end of
the experiments, the cells were treated as described above,
and the number of viable cells and (3H)thymidine incorporation were calculated. A concentration of 2% was
determined by preliminary experiments to maximize the
difference between premetaformin and postmetformin
treatments. Use of 5% serum increased the absolute number of cells and thymidine incorporation but decreased
the differences.
Reagents

The antibodies for phospho-AMPKa (Thr172; #2535),
AMPKa (#2603), phospho-ribosomal protein S6 (phospho-rpS6) (Thr389; #2215), rpS6 (#2217), phosphop44/42 MAPK (ERK1/2; Thr202/Tyr204; #4370), p44/
42 MAPK (ERK1/2; #9102), cyclin D1 (#2922), p27
(#2552), and b-actin (#4967) were all purchased from
Cell Signaling Technology Inc (Danvers, Mass). Antibodies against topoisomerase IIa (sc-56805) were purchased
from Santa Cruz Biotechnology (Santa Cruz, Calif). Antibodies against Ki-67 (M7240) were purchased from Dako
Denmark A/S (Glostrup, Denmark).
Immunohistochemical Analysis

Cell proliferation in endometrial cancer tissues was evaluated by immunohistochemical staining of Ki-67 (positive during all cell cycle stages except for G0)15 and
topoisomerase IIa (positive during S-/G2/M-phase).16,17
Three-lm thick sections were briefly microwaved in
10 mM of citrate buffer (pH 6.0) and immunostained for
Ki-67 and topoisomerase IIa. The Envision FLEX system
(K8000; Dako Denmark A/S) was used for each antibody
to observe the immunostaining using an Autostainer
S3400 (Dako Denmark A/S). The primary antibodies
were incubated at room temperature for 60 minutes at a
2988

dilution of 1:100. The secondary antibody (Envision
FLEX/HRP; Dako Denmark A/S) was incubated at room
temperature for 60 minutes, and 3,30 -diaminobenzidine
tetrahydrochloride (Dako Denmark A/S) was used as a
chromogen. The samples were then counterstained with
hematoxylin. Labeling indices for Ki-67 and topoisomerase IIa were presented as the percentage of immunoreactive nuclei of 500 tumor cells.
Endometrial cancer specimens embedded in paraffin
blocks were retrospectively collected from 10 patients
with endometrioid adenocarcinoma who underwent surgery at Chiba University Hospital. Paired specimens
obtained at the time of preoperative biopsy and at surgery
were stained for Ki-67 and topoisomerase IIa. These
patients did not receive metformin, and these specimens
were used only to assess the natural change of proliferation
markers between 2 intervals.
Western Blot Analysis

Frozen tissue samples were thawed on ice, homogenized
using a TissueRuptor (Qiagen, Hilden, Germany), and
lysed in Complete-M lysis buffer (Roche Applied Science,
Tokyo, Japan) containing Halt phosphatase inhibitor
cocktail (Thermo Fisher Scientific Inc, Wayne, Mich).
Lysates (10 lg of protein) were resolved by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (GE Healthcare
Japan, Tokyo, Japan). Antibodies were the same as those
used for immunohistochemical analyses. The primary
antibodies were diluted (1:2000 for phospho-ERK1/2 and
ERK1/2; 1:1000 for phospho-rpS6, rpS6, cyclin D, and
p27; and 1:5000 for b-actin) and incubated overnight at
4 C. The secondary antibody (enhanced chemiluminescence [ECL] horseradish peroxidase-conjugated antirabbit
immunoglobulin G and antimouse immunoglobulin G;
GE Healthcare) was incubated at room temperature for
60 minutes. Signals were detected using the ECL Plus or
ECL Advance Western Blotting Detection Kit (GE
Healthcare). Signal intensity was quantified using a densitometer (CS Analyzer version 3.0 software; ATTO, Tokyo, Japan) and normalized to b-actin levels.
Metformin Concentration in Patient Tissues

Tissue homogenates and plasma samples were deproteinized using methanol and subjected to liquid
chromatography-mass spectrometry analysis. Liquid
chromatography was performed at ambient temperature
using the Shimazu Prominence LC system (Shimadzu Scientific Instruments, Kyoto, Japan) with Capcell Pak columns (5 lm, 50 3 2 mm; Shiseido Co Ltd, Tokyo,
Cancer

October 1, 2014

Metformin Effects on Endometrial Cancer/Mitsuhashi et al

TABLE 1. Patient Characteristics
No. (%)
Median age (range), y
Histology
Endometrioid adenocarcinoma, grade 1a
Endometrioid adenocarcinoma, grade 2a
Stagea
IA
IB
II
IIIA
IIIC
75-g OGTT
Normal
Impaired glucose tolerance
DM type
Mean HOMA-R (range)
2.5
Mean BMI (range)
25

51 (27-72)
25 (81)
6 (19)
19
6
1
2
3

(61)
(19)
(3)
(6)
(10)

12 (39)
13 (42)
6 (19)
3.2 (0.6-9.8)
20 (65)
28 (18-41)
19 (61)

Abbreviations: BMI, body mass index; DM, diabetes mellitus; HOMA-R,
homeostasis model assessment of insulin resistance; OGTT, oral glucose
tolerance test.
a
The International Federation of Gynecology and Obstetrics (FIGO) stage
and histological grade.

Japan) and 10 mM of ammonium acetate with methanol
at a ratio of 65:35 (volume/volume) as the mobile phase.
Mass spectrometry was performed using the Applied Biosystems Sciex API 4000 mass spectrometer (Applied Biosystems Sciex, Foster City, Calif) with electrospray
ionization for ion production. Detection was performed
using a multiple reaction monitoring mode, with the transition of the protonated molecular ions of metformin at
m/z 130!71.
Statistical Analysis

The statistical analysis for the cell proliferation assay was
performed using the Mann-Whitney U test. Means, 95%
confidence intervals (95% CIs), and standard deviations
were calculated for continuous variables. Comparisons
between paired values were made using the Wilcoxon
signed rank test. All comparisons were planned, and the
tests were 2-sided. A P value of < .05 was considered statistically significant. All statistical analyses were performed
using SAS software (version 9.3; SAS Institute Inc, Cary,
NC) and SPSS software (version 20; IBM-SPSS Inc, Chicago, Ill).
RESULTS
Patient Characteristics

A total of 31 patients were included in the current study,
and patient clinical characteristics are listed in Table 1.
The median patient age was 51 years (range, 27 years-72
Cancer

October 1, 2014

years). Nineteen patients (61%) had a body mass index
of  25 (mean, 28; range, 18-42), and 20 patients (65%)
were insulin-resistant, as indicated by a homeostasis model
assessment of insulin resistance (HOMA-R) score of 2.5
(mean score, 3.2; range, 0.6-9.8). Nineteen patients
(61%) had abnormal glucose tolerance, including 5
patients with a BMI < 25 and 6 patients with a HOMAR < 2.5.
Cell Proliferation in Endometrial Cancer Tissues

Preoperative metformin treatment resulted in significantly reduced Ki-67 expression in 28 patients (90%)
(labeling index reduced from 51.0 [95% CI, 42.9-59.1]
to 30.3 [95% CI, 21.4-39.3]; P < .001) and reduced topoisomerase IIa expression in 25 patients (81%) (labeling
index reduced from 49.9 [95% CI, 41.4-58.4] to 28.5
[95% CI, 23.0-34.0]; P < .001) (Fig. 1A-F). This corresponded to a mean proportional decrease of 44.2% in the
Ki-67 labeling index (95% CI, 35.4-53.0) and 36.4% in
the topoisomerase IIa labeling index (95% CI, 26.746.0). To confirm this finding was not the result of a natural change between 2 sampling intervals, we conducted a
supplemental retrospective analysis on 10 additional
patients who were not administered metformin. No significant changes in either Ki-67 or topoisomerase IIa
expression were found (Table 2).
Using samples from 15 patients, we then examined
changes in 2 cell signaling pathways through which metformin reportedly inhibits cell proliferation: AMPK/mTOR/
rpS6 and MAPK pathways.4,5,18 Metformin administration resulted in significantly increased phospho-AMPK levels (mean proportional increase of 113.2%; 95% CI, 13.6212.8 [P 5 .03]) and significantly decreased phospho-rpS6
levels (mean proportional decrease of 53.2%; 95% CI,
36.8-69.5 [P 5 .002]) (Fig. 2A-B). In addition, metformin
significantly decreased phosphorylated extracellular signalregulated kinase (ERK1/2) levels (mean proportional
decrease of 65.8%; 95% CI, 45.6-95.9 [P 5 .002]),
thereby activating p27 (mean proportional increase of
59.0%; 95% CI, 12.5-105.5 [P 5 .02]) and inhibiting
cyclin D1 (mean proportional decrease of 20.9%; 95% CI,
17.1-58.9 [P 5 .67]) (Fig. 2C-E).
Tissue Metformin Concentrations In Vivo

After preoperative oral administration of 3 doses of
750 mg each of metformin daily for 4 to 9 weeks, plasma
concentrations on the day of the second oral glucose tolerance test were 1.7 lM and 6.8 to 18.1 lM before and 2
hours after the patient ingested the last dose, respectively
(Fig. 3A). Concentrations in endometrial cancer tissues
2989

Original Article

Figure 1. Preoperative metformin administration decreases immunostaining of Ki-67 and topoisomerase IIa (Topo IIa) in endometrial cancer tissues. Representative changes in immunostaining are shown for paired specimens: Ki-67 (A) before and (B) after
treatment and topoisomerase IIa (C) before and (D) after treatment. The change in labeling indices, expressed as a percentage
of positively stained nuclei among a total of 500 nuclei, are shown for each pair and evaluated using the Wilcoxon signed rank
test: (E) Ki-67 and (F) topoisomerase IIa. Pre indicates before the initiation of metformin treatment; Post, after metformin
treatment.

TABLE 2. Effect of Preoperative Metformin on Ki-67 and Topoisomerase IIa Expressiona
Measurement of Labeling Index
Proliferation Marker

Treatment Group

No.

Ki-67

Metformin-treated
No metformind
Metformin-treated
No metformind

31
10
31
10

Topoisomerase IIa

Pretreatmentb
Mean (95% CI)
51.0
45.2
49.9
50.0

(42.9-59.1)
(34.7-55.7)
(41.4-58.4)
(39.0-60.6)

Posttreatmentc
Mean (95% CI)
30.3
46.4
28.5
49.6

(21.4-39.4)
(34.9-58.0)
(23.0-34.0)
(41.1-58.0)

P
<.001
.12
<.001
.87

Abbreviation: 95% CI, 95% confidence interval.
a
Group comparisons were performed using the Wilcoxon matched pairs test.
b
Preoperative biopsy samples.
c
Hysterectomy samples.
d
Retrospectively collected endometrial cancer specimens.

2990

Cancer

October 1, 2014

Metformin Effects on Endometrial Cancer/Mitsuhashi et al

Figure 2. Preoperative metformin administration changes cell proliferation signaling. Cell signaling molecules in endometrial cancer tissues were detected by Western blot analysis, quantitated by densitometry, and normalized to b-actin. The results are
expressed as a percentage of paired controls obtained from the same patient before metformin administration and evaluated
using the Wilcoxon signed rank test. Columns and bar graphs represent the mean 6 the standard deviation of the mean of at least
15 paired samples. The upper inset includes representative results of 3 paired sample comparisons. (A) Phospho-adenosine
monophosphate-activated protein kinase (AMPK) and AMPK are shown; (B) phospho-ribosomal protein S6 (rpS6) and rpS6 are
shown; (C) phospho-extracellular signal-regulated kinase 1/2 (ERK1/2) and ERK1/2 are shown; (D) p27 is shown; and (E) cyclin D1
is shown. Pre indicates before the initiation of metformin treatment; Post, after metformin treatment.

Growth-Stimulatory Potential of Sera

metformin decreased insulin and glucose by approximately 40% and 25%, respectively. In addition, oral metformin decreased the levels of circulating IGF-1 by
approximately 15%.
Metformin lowered the thymidine uptake activity of
sera in all 15 patients (Fig. 4). It is interesting to note that
thymidine uptake remained low even 2 hours after loading with 75 g glucose. Moreover, serum insulin and glucose levels increased, whereas IGF-1 and leptin levels
remained low.

We assessed the humoral factor-mediated action of metformin on cell proliferation. Preoperative metformin use
caused significant decreases in the profiles of circulating
factors, such as insulin, glucose, insulin-like growth factor
1 (IGF-1), and leptin (Table 3). Oral administration of

DISCUSSION
To the best of our knowledge, the current study is the first
prospective evidence that an antidiabetic dose of metformin suppresses endometrial cancer cell growth in vivo.

were 1.2 to 5.1 lmol/kg wet weight, which equated to
approximately 20% of the plasma concentration, assuming that 1 g of wet tissue is equivalent to 1 mL.
Using the endometrial cancer-derived cell lines, we
then found that at least 1 mM of metformin was necessary
to inhibit cell proliferation in vitro (Fig. 3B-E), a dose < 1/400 of the minimum concentration (approximately
1 mM) required to suppress growth in vitro.

Cancer

October 1, 2014

2991

Original Article

Figure 3. Metformin indirectly inhibits the proliferation of endometrial cancer cells. (A) Metformin concentration in plasma and
endometrial cancer tissues is shown. Plasma samples were obtained before or 2 hours after metformin administration on the day
of the second oral glucose tolerance test, whereas endometrial tissues were obtained 2 hours after metformin administration. The
connecting lines represent samples obtained from the same patients. A plasma sample without metformin ingestion was included
as an assay control. (B-E) Cell proliferation and thymidine incorporation assays of Ishikawa cells and HEC-IB cells, respectively,
are shown. The results are presented as the means 6 the standard errors of the mean for at least 3 independent experiments
(n 5 6). Asterisks indicate significant differences compared with metformin-free controls (P <.05, Mann-Whitney U test).

TABLE 3. Changes in Metabolic Profiles After
Preoperative Administration of Metformina

BMI
Insulin, U/mL
Glucose, g/dL
HOMA-R
IGF-1, ng/mL
Leptin, ng/mL
Adiponectin, mg/mL

Pretreatmentb
Mean (95% CI)

Posttreatmentb
Mean (95% CI)

P

30.1 (26.2-34.0)
14.9 (10.0-19.9)
105 (98-113)
3.9 (2.5-5.3)
132 (99-165)
14.8 (10.2-19.3)
9.1 (5.3-128)

29.7 (25.7-33.7)
8.9 (4.7-13.0)
89 (83-94)
2.0 (1.0-3.0)
113 (86-141)
12.2 (7.4-17.0)
8.2 (4.1-12.3)

.26
.02
.01
.02
.01
.03
.12

95% CI, 95% confidence interval; BMI, body mass index; HOMA-R, homeostasis model assessment of insulin resistance; IGF-1, insulin-like growth
factor 1.
a
Group comparisons were performed using the Wilcoxon matched pairs
test.
b
Fasting level.

We found that metformin reduced the expression of
cell proliferation markers by approximately 50%. To our
knowledge this is the most significant difference among
studies that have evaluated cancer tissue growth during
2992

metformin administration.19-21 Only 3 studies to date have
assessed the in vivo effect of metformin on cancer tissue, all
of which were histological studies on breast cancer tissues
obtained by preoperative needle biopsy and mastectomy.
Bonanni et al examined changes in Ki-67 staining in
breast cancer tissues harvested from nondiabetic women
who received metformin (850 mg/twice a day for 4
weeks).19 Overall, the effect of metformin on the Ki-67
proliferative index was not statistically significant. However, metformin administration caused an insignificant
decrease (10.5%) in the Ki-67 index of insulin-resistant
women ( 2.8 HOMA-R index) and a significant
increase (11%) in insulin-sensitive women (< 2.8
HOMA-R index). Therefore, the association between
metformin and the HOMA-R index was statistically significant (P 5 .045). This indicates that metformin treatment is beneficial for insulin-resistant women only when
compared with medication-free insulin-sensitive women.
However, the detected benefits were marginal (P 5 .045),
and multiple testing may have resulted in nonsignificant
Cancer

October 1, 2014

Metformin Effects on Endometrial Cancer/Mitsuhashi et al

Figure 4. Humoral factors were responsible for the stimulatory action of metformin on thymidine uptake. An ex vivo
assay for DNA synthesis-stimulatory activity of patient serum
is shown. Plasma samples were obtained prior to or 2 h after
metformin administration on the day of the second OGTT.
Thymidine uptake by Ishikawa cells is plotted on the vertical
axis. Connecting lines represent paired samples obtained
from the same patients. The table indicates changes in metabolic profiles after preoperative metformin administration
(n 5 15). NS indicates not significant; OGTT, oral glucose tolerance test; HOMA-R, homeostasis model assessment of insulin
resistance; N.E., not evaluated; IGF-1, insulin-like growth factor 1. *Five cases that were continuously sampled until 2
hours after OGTT.

results. Hadad et al evaluated tumor cell growth in
patients with breast cancer and reported that preoperative
metformin treatment (1000 mg/day) for 2 weeks significantly decreased the Ki-67 index by 3.4% relative to baseline values.20 However, insulin levels were measured only
once during a preoperative nonfasting period, thereby
limiting interpretation of the results. Recently, Niraula
et al conducted a similar study in patients with breast cancer and reported that preoperative metformin treatment
(1500 mg/day) for 2 to 3 weeks significantly decreased the
Ki-67 index by approximately 8% relative to baseline
values.21
Thus, 2 of the 3 studies of metformin use in patients
with breast cancer demonstrated a significant reduction in
Cancer

October 1, 2014

the Ki-67 index; however, the changes were subtle and
heterogeneous between individuals. In comparison, the
results of the current study demonstrated a more profound (approximately 50%) and consistent decrease in
proliferation.
This finding may be explained by the differences in
target tissues, clinical demography, and duration of metformin administration. First, the planned dose of metformin in the current study was 2250 mg/day, whereas
previous studies used 1000 to 1700 mg/day. Second, we
studied the effects of metformin on patients with type I
endometrial cancer, a malignancy more commonly associated with insulin resistance and diabetes than breast
cancer.22,23
In addition, endometrial cancer has other advantages over breast cancer as an in vivo study model. Preoperative total ablation of the endometrial cavity is
obligatory for diagnosis; however, endometrial tissue will
regenerate in several weeks, thus providing a sufficient
amount of tissue for repetitive analyses with minimal ethical difficulties. Moreover, total ablation eliminates the
possibility that the pathological diagnosis is skewed
because of limited sampling, whereas in patients with
breast cancer, preoperative evaluation is limited to the
core diagnostic biopsy samples. Given the histological
response and accessibility to tissues samples, we propose
that endometrial cancer is a better-suited model for
window-of-opportunity clinical trials with metformin.
In vitro experiments have demonstrated that metformin inhibits cancer cell growth through the activation of
AMPK and the resulting inhibition of the mTOR/S6K
pathway.4-9 Recent reports have identified the MAPK
pathway as an additional growth inhibition target; metformin inhibits MAPK and increases phosphorylation of
p27, thereby resulting in cell cycle inhibition.8,24,25 The
results of the current study confirmed similar effects of
metformin in vivo; metformin intake activated AMPK
and inhibited MAPK in the endometrium.
There is currently controversy regarding whether
metformin inhibits cancer cell growth directly or indirectly. This is based on experimental findings that the
concentration needed to inhibit cell growth is much
higher (approximately  1000 times) than that expected
in patient sera.11 Supporting the indirect mechanism,
metformin prevented carcinogen-induced lung tumorigenesis in mice through the suppression of mTOR.26
Rather than directly activating AMPK, metformin administration resulted in downregulation of phosphorylated
IGF-1 receptor/insulin receptor, Akt, and ERK in mice
lung tissues. Thus, the findings supported the indirect
2993

Original Article

mechanism of metformin, in which metformin reduces
IGF-1 production from liver, thereby resulting in
decreased mTOR and ERK levels.
To address the mechanism of action, we first compared the metformin concentrations in vitro and in vivo
and found that the concentration in tissues was < 1/400
times lower than that of the minimum requirement to inhibit cell growth in vitro. The enhanced responses
observed in vivo might be explained by metformininduced changes in humoral factor(s). To assess this possibility, we performed an ex vivo assay and found that metformin reduced the growth-supporting potential
of patient sera. Among the humoral factors examined,
IGF-1 and leptin, but not insulin, were factors potentially
responsible for this result. In fact, IGF-1 is known to play
an important role in tumorigenesis and the promotion of
endometrial cancer.27-29 Leptin has also been shown to
stimulate endometrial cell proliferation through the activation of signal transducer and activator of transcription 3
(STAT3), AKT, and MAPK signaling pathways.30,31
Although these findings are compatible with an indirect action of metformin, additional confirmation is necessary because there are several alternative explanations.
First, we estimated the concentration in tissues by measuring tissue mass; thus, we did not measure the actual concentration of metformin in cancer cells in vivo. It might
be possible that organic anion transporter-1, a powerful
transporter of metformin expressed in liver cells,32 may
concentrate metformin in vivo, resulting in a higher concentration than we calculated as a mass average. Another
possibility is that the established cancer cell line used in
the current study lost sensitivity to metformin, for example by no longer expressing the transporter. Third, it is
unknown whether the growth-supporting potential
detected by the ex vivo assay is a true reflection of the in
vivo potential. Further experiments are necessary to define
the action of metformin in vivo.
Recently, 2 retrospective studies revealed that metformin use was associated with improved recurrence-free
survival and overall survival.33,34 In these studies, 24% to
25% of patients with endometrial cancer were diabetic,
and 50% of these diabetic patients with cancer used metformin. Greater than 80% of patients with endometrial
cancer were overweight or obese and were insulinresistant. In this regard, the results of the current study
clarified that metformin reduced levels of glucose, insulin,
IGF-1, leptin, and other factors, an important mechanism
for the management of endometrial cancer.
There were several limitations to the current study,
including the lack of a placebo control. In this study, we
2994

did not consider natural changes in cell proliferation
markers between the 2 sampling times, which were separated by an average 4-week interval. Therefore, we conducted supplemental retrospective analyses on 10
additional patients who were not administered metformin. The results indicated no significant changes in any
proliferation markers between the paired samples from
the same individuals.
Although further studies to identify the humoral factor(s) that may mediate the actions of metformin are warranted, the findings of the current study provide a
reasonable basis for the initiation of clinical trials using
antidiabetic doses of metformin for the treatment of
patients with endometrial cancer.
FUNDING SUPPORT
Supported in part by a grant from the Japan Society for Promotion
of Science (grant numbers 24592504, 23132503, 25670694, and
25253092). The funding source had no role in the study design,
data collection, data analysis, data interpretation, or writing of the
report.

CONFLICT OF INTEREST DISCLOSURES
Dr. Sato has received a grant from Kowa Souyaku, acted as a paid
member of the Independent Data Monitoring Committee of Pfizer
Japan Inc, received speaking fees from Elekta, received lecture fees
from Siemens, and acted as a paid member of the advisory committee for the Ministry of Health, Labor and Welfare of Japan and the
Japan Medical Association Center for Clinical Trial.

REFERENCES
1. Foretz M, Hebrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a
decrease in hepatic energy state. J Clin Invest. 2010;120:2355-2369.
2. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer
risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3:1451-1461.
3. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD.
Metformin and reduced risk of cancer in diabetic patients. BMJ.
2005;330:1304-1305.
4. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269-10273.
5. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N.
Metformin inhibits mammalian target of rapamycin-dependent
translation initiation in breast cancer cells. Cancer Res. 2007;67:
10804-10812.
6. Gotlieb WH, Saumet J, Beauchamp MC, et al. In vitro metformin
anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol.
2008;110:246-250.
7. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin
induces apoptosis of pancreatic cancer cells. World J Gastroenterol.
2008;14:7192-7198.
8. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 2008;27:3576-3586.
9. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, BaeJump VL. Metformin is a potent inhibitor of endometrial cancer cell
proliferationâ€“implications for a novel treatment strategy. Gynecol
Oncol. 2010;116:92-98.

Cancer

October 1, 2014

Metformin Effects on Endometrial Cancer/Mitsuhashi et al

10. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic
complete responses to neoadjuvant chemotherapy in diabetic patients
with breast cancer. J Clin Oncol. 2009;27:3297-3302.
11. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends
Endocrinol Metab. 2013;24:469-480.
12. Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological
evidence. Endocr Relat Cancer. 2012;19:F1-F8.
13. Burzawa JK, Schmeler KM, Soliman PT, et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J
Obstet Gynecol. 2011;204:355.e1-355.e7.
14. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA,
Morgan CL. Mortality after incident cancer in people with and
without type 2 diabetes: impact of metformin on survival. Diabetes
Care. 2012;35:299-304.
15. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the
unknown. J Cell Physiol. 2000;182:311-322.
16. Heck MM, Earnshaw WC. Topoisomerase II: a specific marker for
cell proliferation. J Cell Biol. 1986;103:2569-2581.
17. Ito K, Sasano H, Yabuki N, et al. Immunohistochemical study of
Ki-67 and DNA topoisomerase II in human endometrium. Mod
Pathol. 1997;10:289-294.
18. Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells.
Cell Cycle. 2009;8:2031-2040.
19. Bonanni B, Puntoni M, Cazzaniga M, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.
J Clin Oncol. 2012;30:2593-2600.
20. Hadad S, Iwamoto T, Jordan L, et al. Evidence for biological effects
of metformin in operable breast cancer: a pre-operative, window-ofopportunity, randomized trial. Breast Cancer Res Treat. 2011;128:
783-794.
21. Niraula S, Dowling RJ, Ennis M, et al. Metformin in early breast
cancer: a prospective window of opportunity neoadjuvant study.
Breast Cancer Res Treat. 2012;135:821-830.
22. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones,
and endometrial cancer risk: a synthetic review. Cancer Epidemiol
Biomarkers Prev. 2002;11:1531-1543.

Cancer

October 1, 2014

23. Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: a significant risk factor of endometrial cancer. Gynecol Oncol. 2012;125:
751-757.
24. Zhuang Y, Miskimins WK. Cell cycle arrest in metformin treated
breast cancer cells involves activation of AMPK, downregulation of
cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008;3:18.
25. Malki A, Youssef A. Antidiabetic drug metformin induces apoptosis
in human MCF breast cancer via targeting ERK signaling. Oncol
Res. 2011;19:275-285.
26. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD,
Dennis PA. Metformin prevents tobacco carcinogen-induced lung
tumorigenesis. Cancer Prev Res. 2010;3:1066-1076.
27. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological
evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-591.
28. Lukanova A, Zeleniuch-Jacquotte A, Lundin E, et al. Prediagnostic
levels of C-peptide, IGF-1, IGFBP 21, 22 and 23 and risk of endometrial cancer. Int J Cancer. 2004;108:262-268.
29. Cust AE, Allen NE, Rinaldi S, et al. Serum levels of C-peptide,
IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the
European prospective investigation into cancer and nutrition. Int J
Cancer. 2007;120:2656-2664.
30. Sharma D, Saxena NK, Vertino PM, Anania FA. Leptin promotes
the proliferative response and invasiveness in human endometrial
cancer cells by activating multiple signal-transduction pathways.
Endocr Relat Cancer. 2006;13:629-640.
31. Gao J, Tian J, Lv Y, et al. Leptin induces functional activation of
cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/
AKT pathways in human endometrial cancer cells. Cancer Sci. 2009;
100:389-395.
32. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH,
Sugiyama Y. Involvement of organic cation transporter 1 in hepatic
and intestinal distribution of metformin. J Pharmacol Exp Ther.
2002;302:510-515.
33. Ko EM, Walter P, Jackson A, et al. Metformin is associated with
improved survival in endometrial cancer. Gynecol Oncol. 2014;132:
438-442.
34. Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use
and endometrial cancer survival. Gynecol Oncol. 2014;132:236-240.

2995

